A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Public Health, Biostatistics, Experimental Design +10

Response criteria for phase II studies of supratentorial malignant glioma.

David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations

Medicine, Oncology, Radiology +17

Genomic Analysis of Non- <i>NF2</i> Meningiomas Reveals Mutations in <i>TRAF7</i> , <i>KLF4</i> , <i>AKT1</i> , and <i>SMO</i>

Victoria Clark, E. Zeynep Erson‐Omay, Akdes Serin et al. · Science · 2013 · 887 citations · Full text

Medicine, Genetics, Oncology +16

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 847 citations

Medicine, Oncology, Pharmacology +16

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

Priscilla K. Brastianos, Peleg Horowitz, Sandro Santagata et al. · Nature Genetics · 2013 · 652 citations · Full text

Life Sciences, Genetics, Molecular Biology +11